12.58
price up icon0.72%   0.09
after-market 시간 외 거래: 12.58
loading
전일 마감가:
$12.49
열려 있는:
$12.1
하루 거래량:
1.78M
Relative Volume:
1.17
시가총액:
$1.26B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-26.77
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
-2.40%
1개월 성능:
+20.04%
6개월 성능:
-13.24%
1년 성능:
+23.09%
1일 변동 폭
Value
$11.85
$12.77
1주일 범위
Value
$11.85
$13.22
52주 변동 폭
Value
$7.55
$18.51

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name
명칭
Ars Pharmaceuticals Inc
Name
전화
858-771-9307
Name
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-12-13
Name
최신 SEC 제출 서류
Name
SPRY's Discussions on Twitter

SPRY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SPRY
Ars Pharmaceuticals Inc
12.58 1.26B 0 -44.84M -44.23M -0.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-07 개시 Scotiabank Sector Outperform
2025-02-10 개시 Oppenheimer Outperform
2024-08-20 개시 Cantor Fitzgerald Overweight
2024-08-13 업그레이드 Raymond James Outperform → Strong Buy
2024-08-12 재확인 Leerink Partners Outperform
2024-07-25 개시 Raymond James Outperform
2024-03-05 업그레이드 Leerink Partners Market Perform → Outperform
2024-02-20 업그레이드 William Blair Mkt Perform → Outperform
2023-09-20 다운그레이드 William Blair Outperform → Mkt Perform
2023-01-31 개시 Wedbush Outperform
2023-01-03 개시 William Blair Outperform
2022-12-13 개시 SVB Leerink Outperform
모두보기

Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스

pulisher
Mar 26, 2025

Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st

Mar 26, 2025
pulisher
Mar 26, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance

Mar 26, 2025
pulisher
Mar 25, 2025

Long Term Trading Analysis for (SPRY) - Stock Traders Daily

Mar 25, 2025
pulisher
Mar 24, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor

Mar 24, 2025
pulisher
Mar 22, 2025

ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

neffy From ARS Pharmaceuticals, Inc - Pharmacy Times

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha

Mar 20, 2025
pulisher
Mar 20, 2025

Raymond James maintains $28 target on ARS Pharma stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: ARS Pharmaceuticals Q4 2024 earnings beat expectations - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Sector Update: Health Care - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings -March 20, 2025 at 07:45 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Revenue $86.6M -March 20, 2025 at 07:13 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 EPS $0.48, vs. FactSet Est of $-0.04 Loss - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharma Crushes Q4 with $49.9M Profit as Neffy Launch Gains Momentum - StockTitan

Mar 20, 2025
pulisher
Mar 18, 2025

This company’s epinephrine nasal spray reverses allergic reactions—no needle required - Fast Company

Mar 18, 2025
pulisher
Mar 18, 2025

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company

Mar 18, 2025
pulisher
Mar 14, 2025

(SPRY) Investment Report - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Steward Partners Investment Advisory LLC Raises Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 09, 2025

Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Scotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025
pulisher
Mar 08, 2025

Rhumbline Advisers Buys 1,824 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Ars pharmaceuticals director Laura Shawver sells $560,445 in stock By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients - Reuters

Mar 07, 2025
pulisher
Mar 07, 2025

San Diego biotech gets FDA approval for EpiPen alternative for kids - MSN

Mar 07, 2025
pulisher
Mar 07, 2025

Exploring High Growth Tech Stocks in the US Market - Simply Wall St

Mar 07, 2025
pulisher
Mar 07, 2025

California biotech company gets FDA approval for EpiPen alternative for kids - East Bay Times

Mar 07, 2025
pulisher
Mar 07, 2025

Scotiabank sets $30 target for ARS Pharmaceuticals stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Scotiabank sets $30 target for ARS Pharmaceuticals stock By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients - Pharmaceutical Executive

Mar 06, 2025
pulisher
Mar 06, 2025

FDA Approves Low-Dose Neffy Epinephrine Spray for Young Kids - Allergic Living

Mar 06, 2025

Ars Pharmaceuticals Inc (SPRY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):